Rafarma Pharmaceuticals, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Sergey Brusnitsin
- Full Time Employees
- 700
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 49 West 9000 South Sandy UT United States of America 84070
- IPO Date
- Dec 11, 2012
- Website
- rafarma.si
- Similar Companies
- Business
- Rafarma Pharmaceuticals, Inc. (RAFA) is a multi-product pharmaceutical company that manufactures and markets a broad range of generic antibiotics, specialty pharmaceuticals, sterile injectables, ophthalmic solutions, suspensions, emulsions, film-coated tablets, and soft gel capsules primarily in Europe and Asia; its portfolio encompasses cephalosporin-based products, non-beta lactam antibiotics, anti-cancer drugs, anti-thrombotic agents including apixaban, clopidogrel besilate, ticagrelor, and antithrombotic combinations; glaucoma and ocular hypertension treatments such as bimatoprost, brimonidine, dorzolamide, latanoprost, tafluprost, travoprost and numerous fixed-dose combinations with timolol; anti-inflammatories and glucocorticoids like bromfenac, dexamethasone, difluprednate, fluorometholone; anti-infectives including amikacin, ciprofloxacin-dexamethasone, levofloxacin, moxifloxacin, tobramycin-dexamethasone; products for allergic conjunctivitis such as olopatadine and sodium cromoglycate; cardiovascular therapies like iloprost for peripheral arterial occlusive disease and pulmonary hypertension, iron deficiency treatments including ferric carboxymaltose and iron sucrose complex; migraine treatments with eletriptan; hypercholesterolemia agents such as ezetimibe and rosuvastatin calcium; secondary hyperparathyroidism drugs like paricalcitol; nausea treatments with palonosetron; and others including dutasteride for benign prostatic hyperplasia, zoledronic acid for skeletal events in malignancies, alongside emerging offerings like perfluorohexyloctane for dry eye disease and nanostructured microspheres for liver cancer radioembolization. The company operates as a contract development and manufacturing organization (CDMO) with a focus on complex sterile forms, nuclear medicine, biotechnology products, and research in molecular biology, immunology, and sustainable packaging, targeting markets in Russia, Kazakhstan, Israel, El Salvador, Sri Lanka, Hong Kong, and the European Union with regulatory dossiers available or planned through 2027 for products like tafluprost/timolol preservative-free and latanoprostene bunod. Founded in 1930 and headquartered in Sandy, Utah, Rafarma Pharmaceuticals pursues global expansion through asset acquisitions and projects in multiple countries without diluting shareholder value, alongside recapitalization via preferred shares, GAAP audit submissions incorporating new assets, and a planned shareholders meeting before February 2025 to restructure capital and reinvest for enhanced manufacturing and R&D capabilities aiming for a $2 billion valuation by year-end 2025; it maintains a collaboration with PlantEXT Ltd. for medical cannabis suppositories targeting inflammatory bowel disease and was formerly known as Johnston Acquisition Corp. prior to its October 2012 name change.
Rafarma Pharmaceuticals to Present at the Virtual Life Science Investor Forum March 13th
Rafarma pharmaceutical updates: registration of Rafarma microspheres in South Korea
Rafarma pharmaceutical updates: creation of a joint research and production enterprise in Busan (South Korea) between Rafarma and the Korean pharmaceutical company Woods Medical Care
Rafarma pharmaceutical updates: agreements with Shri Lanka pharmaceutical company Kelun Lifesciences (Pvt) Ltd and El Salvador University
Rafarma Pharmaceutical news update
Rafarma Enters Negotiations With Leading Global Producer of Precious Metals to Localize Production of Platinum-Based Cancer Drugs
Letter to Shareholders from the Chairman of the Board Ilya Shpurov
Rafarma Signs Trilateral Investment Agreement Officially Launching Tashkent Pharmaceutical Plant Build
Rafarma's Global Pharmaceutical Strategy At A Glance
Rafarma To Expand Proton Therapy Centers
Rafarma and Haifa Technopark Enter Talks for Joint Venture
Rafarma Embarks on Aggressive Global Partnerships Plan